Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial

American Heart Journal

Volumn 166, Issue 5, 2013, Pages

  Marso, Steven P ^a   Poulter, Neil R ^b   Nissen, Steven E ^c   Nauck, Michael A ^d   Zinman, Bernard ^e   Daniels, Gilbert H ^f   Pocock, Stuart ^g   Steinberg, William M ^h   Bergenstal, Richard M ⁱ   Mann, Johannes F E ^j   Ravn, Lasse Steen ^k   Frandsen, Kirstine Brown ^k   Moses, Alan C ^k   Buse, John B ^l  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c LERNER RESEARCH INSTITUTE   (United States)

^d DIABETESZENTRUM BAD LAUTERBERG   (Germany)

^e MOUNT SINAI HOSPITAL   (Canada)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^h GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

ⁱ INTERNATIONAL DIABETES CENTER   (United States)

^j UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^k NOVO NORDISK A S   (Denmark)

^l UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; CALCITONIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ADULT; ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETIC RETINOPATHY; DISEASE DURATION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREATITIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; STUDY DESIGN;

EID: 84886946727     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.07.012     Document Type: Article

References (25)

1. G. Danaei, M.M. Finucane, and Y. Lu National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants Lancet 378 2011 31 40
2. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants 2007 U.S. Department of Health and Human Services, Centers for Disease Control and Prevention Atlanta, GA
3. N. Sarwar, P. Gao, and S.R. Seshasai Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies Lancet 375 2010 2215 2222
4. American Diabetes Association Standards of medical care in diabetes - 2013 Diabetes Care 36 Suppl. 1 2013 S11 S66
5. S.E. Inzucchi, R.M. Bergenstal, and J.B. Buse Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
6. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
7. H.C. Gerstein, M.E. Miller, and R.P. Byington Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559
8. United States Food and Drug Administration Guidance for Industry Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes 2008 U.S. Department of Health and Human Services
9. J.J. Holst The physiology of glucagon-like peptide 1 Physiol Rev 87 2007 1409 1439
10. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
11. J.J. Meier GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus Nat Rev Endocrinol 8 2012 728 742
12. R.R. Henry, J.B. Buse, and G. Sesti Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program Endocr Pract 17 2011 906 913
13. International Diabetes Federation Global guideline for type 2 diabetes 2005 International Diabetes Federation Brussels
14. American Association of Clinical Endocrinologists American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus Endocr Pract 13 Suppl. 1 2007 1 68
15. National Collaborating Center for Chronic Conditions and the Center for Clinical Practice. Clinical Guideline 87 Type 2 diabetes: the management of type 2 diabetes 2009.
16. D.M. Nathan, J.B. Buse, and M.B. Davidson Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 2009 193 203
17. American Diabetes Association Standards of medical care in diabetes - 2010 Diabetes Care 33 Suppl. 1 2010 S11 S61
18. European Agency for the Evaluation of Medicinal Products Points to consider on switching between superiority and non-inferiority 2000 European Agency for the Evaluation of Medicinal Products London
19. M.D. Rothmann, B.L. Wiens, and I.S.F. Chan Design and analysis of non-inferiority trials 2011 Chapman & Hall Boca Raton, Florida
20. R.E. Pratley, M. Nauck, and T. Bailey Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial Lancet 375 2010 1447 1456
21. D. Lorber GLP-1 receptor agonists: effects on cardiovascular risk reduction Cardiovasc Ther 31 2013 238 249
22. A. Garber, R. Henry, and R. Ratner Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 373 2009 473 481
23. J.P. Courreges, T. Vilsboll, and M. Zdravkovic Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes Diabet Med 25 2008 1129 1131
24. T. Forst, G. Michelson, and F. Ratter Addition of liraglutide in patients with type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function Diabet Med 29 2012 1115 1118
25. K. Thygesen, J.S. Alpert, and H.D. White Universal definition of myocardial infarction J Am Coll Cardiol 50 2007 2173 2195